rotavirus vaccine (University of Oxford)

The rotavirus vaccine is a live-attenuated viral vaccine designed to prevent rotavirus gastroenteritis, a leading cause of severe diarrhea and dehydration in infants. In the context of clinical research led by the University of Oxford, such as the evaluation of optimized infant immunization schedules (e.g., the SEMP trial), the vaccine is administered alongside other routine childhood immunizations, including the 13-valent pneumococcal conjugate vaccine (PCV13) and the meningococcal B vaccine. The vaccine, typically the monovalent Rotarix (RV1) in the UK, works by inducing mucosal and systemic immunity, primarily through the production of secretory IgA antibodies against the virus's outer capsid proteins. While the input name associates the vaccine with invasive pneumococcal disease, this reflects the broader trial context where the rotavirus vaccine is co-administered with pneumococcal vaccines rather than being a treatment for pneumococcal disease itself.

Brand names

RotarixRotaTeq

Other names

RV1RV-1RV 1human rotavirus vaccinelive-attenuated rotavirus vaccine